GlassScriptPhysician profile
Robert Benjamin Saldana
NPI 1063593002
$14,632.10
in general payments reported to CMS, 2019-2025
16 companies · $22.55 in 2025
The $22.55 reported for 2025 was less than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,090 · 2020: $3,060 · 2021: $2,998 · 2022: $221 · 2023: $704 · 2024: $536 · 2025: $22.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12,674.20 | 2019-2021 | |
| Csl Behring | $441.49 | 2020-2023 | Kcentra |
| Abbvie INC. | $405.34 | 2021-2024 | Dalvance |
| Janssen Pharmaceuticals, INC | $275.66 | 2024 | Xarelto |
| Melinta Therapeutics, LLC | $222.58 | 2019-2023 | Kimyrsa, Orbactiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.39 | 2019-2025 | Xifaxan |
| Genentech USA, INC. | $130.43 | 2019 | |
| Mindray Ds USA, INC. | $49.06 | 2023 | Te7 Max, Te X |
| Paratek Pharmaceuticals, INC. | $44.35 | 2023 | Nuzyra |
| Alexion Pharmaceuticals, INC. | $37.25 | 2021-2024 | Ultomiris |
| Genzyme Corporation | $32.94 | 2019 | |
| Gilead Sciences, INC. | $28.54 | 2023-2024 | Veklury |
| Ucb, INC. | $27.18 | 2024 | Briviact |
| Ethicon US, LLC | $22.13 | 2021 | |
| Merck Sharp & Dohme LLC | $19.08 | 2024 | Zerbaxa, Dificid, Recarbrio |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $15.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Saldana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.